Nuvalent, Inc. Files 8-K for Other Events
Ticker: NUVL · Form: 8-K · Filed: Apr 7, 2026 · CIK: 0001861560
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Nuvalent filed an 8-K for 'other events' - no specific details yet.
AI Summary
Nuvalent, Inc. filed an 8-K on April 7, 2026, to report other events. The filing does not contain specific financial figures or new material agreements, but serves as a notification of events relevant to the company.
Why It Matters
This filing indicates Nuvalent has reported on events not covered by other standard 8-K items, which could be material to investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for 'other events' and does not disclose specific financial impacts or significant new risks.
Key Players & Entities
- Nuvalent, Inc. (company) — Filer
FAQ
What specific 'other events' are being reported by Nuvalent, Inc. in this 8-K filing?
The filing itself, an 8-K dated April 7, 2026, is categorized under Item 8.01 'Other Events'. However, the provided text does not detail the specific nature of these events.
When was this 8-K filing accepted by the SEC?
The 8-K filing for Nuvalent, Inc. was accepted on April 7, 2026, at 06:33:22.
What is Nuvalent, Inc.'s CIK number?
Nuvalent, Inc.'s CIK number is 0001861560.
What is the business address of Nuvalent, Inc. as listed in the filing?
The business address for Nuvalent, Inc. is ONE BROADWAY, 14TH FLOOR CAMBRIDGE MA 02142.
What is the SIC code for Nuvalent, Inc.?
The SIC code for Nuvalent, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 396 words · 2 min read · ~1 pages · Grade level 9.7 · Accepted 2026-04-07 06:33:22
Key Financial Figures
- $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share NUVL The Nasdaq
Filing Documents
- nuvl-20260407.htm (8-K) — 40KB
- 0001861560-26-000003.txt ( ) — 143KB
- nuvl-20260407.xsd (EX-101.SCH) — 25KB
- nuvl-20260407_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events. On April 7, 2026, Nuvalent, Inc. announced the submission of its New Drug Application to the U.S. Food and Drug Administration for neladalkib in tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nuvalent, Inc. Date: April 7, 2026 By: /s/ Deborah A. Miller Deborah A. Miller, Ph.D. Chief Legal Officer and Secretary